HeimNSIS-B • CPH
add
Novozymes
Við síðustu lokun
416,40 kr.
Dagbil
414,00 kr. - 418,20 kr.
Árabil
378,10 kr. - 485,90 kr.
Markaðsvirði
177,03 ma. DKK
Meðalmagn
614,00 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
CPH
Viðskiptafréttir
Seeking Alpha
fyrir 10 mínútum
Seasonal setup suggests S&P 500 will step higher into the new year: LPL
0,38%
0,50%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 915,85 m. | 61,70% |
Rekstrarkostnaður | 271,75 m. | 52,62% |
Nettótekjur | 31,95 m. | -60,72% |
Hagnaðarhlutfall | 3,49 | -75,70% |
Hagnaður á hvern hlut | — | — |
EBITDA | 150,94 m. | -16,50% |
Virkt skatthlutfall | 29,00% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 260,80 m. | 85,35% |
Heildareignir | 15,25 ma. | 302,43% |
Heildarskuldir | 4,25 ma. | 119,23% |
Eigið fé alls | 11,00 ma. | — |
Útistandandi hlutabréf | 277,90 m. | — |
Eiginfjárgengi | 10,52 | — |
Arðsemi eigna | 1,83% | — |
Ávöxtun eigin fjár | 2,15% | — |
Peningaflæði
Breyting á handbæru fé
| (EUR) | jún. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 31,95 m. | -60,72% |
Handbært fé frá rekstri | 264,05 m. | 74,01% |
Reiðufé frá fjárfestingum | -27,45 m. | 70,98% |
Reiðufé frá fjármögnun | -186,70 m. | -205,10% |
Breyting á handbæru fé | 55,55 m. | 902,56% |
Frjálst peningaflæði | -17,57 m. | 68,87% |
Um
Novozymes A/S is a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange.
On 12 December 2023, it was announced that Novozymes and Danish bioscience company Chr. Hansen had obtained regulatory approval for a merger, and on the following day, the name of the combined company was revealed as Novonesis. Wikipedia
Framkvæmdastjóri
Stofnsett
2000
Vefsvæði
Starfsfólk
10.452
